Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$5.29 -3.6%	$4.47	$1.94 ▼ $12.32	$8.25M	-0.04	958,223 shs	24,289 shs
RNAZ TransCode Therapeutics	$9.88 -1.7%	$9.77	$6.15 ▼ $739.20	$8.20M	1.46	189,602 shs	13,837 shs
SRNE Sorrento Therapeutics	$0.01	$0.00	$0.00 ▼ $0.01	$3.31M	0.85	123,400 shs	149,825 shs
VYNE VYNE Therapeutics	$0.33 +1.0%	$0.92	$0.31 ▼ $4.30	$8.39M	1.76	902,691 shs	1.06 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	+1.48%	-5.83%	+25.92%	+53.39%	+19.57%
RNAZ TransCode Therapeutics	-2.33%	-0.79%	-27.65%	+45.65%	-99.88%
SRNE Sorrento Therapeutics	+20.00%	+25.00%	+140.00%	+252.94%	-33.33%
VYNE VYNE Therapeutics	+2.74%	-0.28%	-77.50%	-66.20%	-81.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVOK Evoke Pharma	0.6867 of 5 stars	0.0	5.0	0.0	2.6	0.0	0.0
RNAZ TransCode Therapeutics	1.9772 of 5 stars	3.5	2.0	0.0	2.7	0.0	0.6
SRNE Sorrento Therapeutics	0.6146 of 5 stars	0.0	2.0	4.3	0.0	0.0	0.0
VYNE VYNE Therapeutics	2.3559 of 5 stars	3.0	2.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,734.01% Upside
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.00	Hold	$6.25	1,796.81% Upside

Current Analyst Ratings Breakdown

Latest SRNE, EVOK, RNAZ, and VYNE Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/31/2025	VYNE VYNE Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	VYNE VYNE Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$12.79M	0.64	N/A	N/A	$2.81 per share	1.88
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$7.37 per share	N/A
SRNE Sorrento Therapeutics	$60.32M	0.05	N/A	N/A	N/A	∞
VYNE VYNE Therapeutics	$500K	16.78	N/A	N/A	$1.53 per share	0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$5.35M	-$2.56	N/A	∞	N/A	-42.07%	-99.48%	-33.58%	11/5/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-378.30%	-186.01%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	-$39.83M	-$0.90	N/A	N/A	N/A	-8,097.69%	-77.57%	-63.09%	11/6/2025 (Estimated)

Latest SRNE, EVOK, RNAZ, and VYNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVOK Evoke Pharma	-$0.30	-$0.62	-$0.32	-$0.62	$3.80 million	$3.75 million
8/14/2025	Q2 2025	RNAZ TransCode Therapeutics	-$8.68	-$4.94	+$3.74	-$5.13	N/A	N/A
8/14/2025	Q2 2025	VYNE VYNE Therapeutics	-$0.23	-$0.13	+$0.10	-$0.13	$0.15 million	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	1.37	1.32
RNAZ TransCode Therapeutics	N/A	5.27	5.27
SRNE Sorrento Therapeutics	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	7.60	7.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
RNAZ TransCode Therapeutics	N/A
SRNE Sorrento Therapeutics	0.02%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	2.29%
RNAZ TransCode Therapeutics	0.01%
SRNE Sorrento Therapeutics	2.60%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	1.56 million	1.52 million	Not Optionable
RNAZ TransCode Therapeutics	9	830,000	834,000	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data
VYNE VYNE Therapeutics	30	25.47 million	24.25 million	Not Optionable

SRNE, EVOK, RNAZ, and VYNE Headlines

Recent News About These Companies

VYNE Therapeutics (NASDAQ:VYNE) Trading 2.7% Higher - Still a Buy?

August 28 at 2:29 AM | americanbankingnews.com

VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

August 19, 2025 | finance.yahoo.com

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

August 14, 2025 | finance.yahoo.com

VYNE Therapeutics reports Q2 EPS (13c) vs (22c) last year

August 14, 2025 | msn.com

VYNE Reports Narrower Loss in Fiscal Q2

August 14, 2025 | aol.comA

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

August 14, 2025 | zacks.com

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

August 14, 2025 | globenewswire.com

Vitiligo Pipeline Outlook Report 2025: Key 18+ Companies and Breakthrough Therapies Shaping the Future Landscape

August 5, 2025 | theglobeandmail.com

Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash Wisely

August 1, 2025 | finance.yahoo.com

Repibresib gel fails to meet endpoints for nonsegmental vitiligo study

August 1, 2025 | healio.comH

Vyne Therapeutics Ends Trial of Repibresib Gel in Nonsegmental Vitiligo

July 31, 2025 | marketwatch.com

VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints

July 31, 2025 | za.investing.com

HC Wainwright & Co. Downgrades VYNE Therapeutics (VYNE)

July 31, 2025 | msn.com

VYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary Endpoint

July 31, 2025 | appliedclinicaltrialsonline.comA

VYNE Therapeutics Shares Sink Premarket Following End to Trial After Endpoint Missed

July 31, 2025 | marketwatch.com

Vyne's lead BET inhibitor fails phase 2 vitiligo trial, sinking stock

July 31, 2025 | fiercebiotech.comF

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

July 31, 2025 | msn.com

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

July 30, 2025 | globenewswire.com

Vyne Therapeutics: A Risky Bet On Upcoming Vitiligo Ph2b Readout

July 28, 2025 | seekingalpha.com

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress

July 11, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE, EVOK, RNAZ, and VYNE Company Descriptions

Evoke Pharma NASDAQ:EVOK

$5.29 -0.20 (-3.64%)

Closing price 04:00 PM Eastern

Extended Trading

$5.10 -0.19 (-3.59%)

As of 05:41 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

TransCode Therapeutics NASDAQ:RNAZ

$9.88 -0.17 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$9.88 0.00 (0.00%)

As of 04:13 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Sorrento Therapeutics NASDAQ:SRNE

$0.0060 0.00 (0.00%)

As of 03:49 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

VYNE Therapeutics NASDAQ:VYNE

$0.33 +0.00 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.33 +0.00 (+0.15%)

As of 05:39 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time